Biogen Idec (Nasdaq: BIIB) reports results from a randomized, multicenter, dose-blinded clinical trial that evaluated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE